COST-EFFECTIVENESS OF LENALIDOMIDE/DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR THALIMODMIDE THERAPY

被引：0
|
作者：
Schey, S. [1 ]
Stern, S. [2 ]
Dhanasiri, S. [3 ]
Brown, R. [2 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] United BioSource Corp, Bethesda, MD USA
[3] Celgene Ltd, Uxbridge, Middx, England
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1087
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [1] Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
    Brown, Ruth E.
    Stern, Sean
    Dhanasiri, Sujith
    Schey, Steve
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (03): : 507 - 514
  • [2] Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales
    Schey, Stephen
    Stern, Sean
    Dhanasiri, Sujith
    Brown, Ruth
    [J]. BLOOD, 2011, 118 (21) : 1789 - 1790
  • [3] Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
    Ruth E. Brown
    Sean Stern
    Sujith Dhanasiri
    Steve Schey
    [J]. The European Journal of Health Economics, 2013, 14 : 507 - 514
  • [4] Cost-effectiveness of lenalidomide in multiple myeloma
    Schey, Steve
    Higginson, Irene
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (03) : 229 - 238
  • [5] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
    Wong, Xin Yi
    Chng, Wee Joo
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
  • [6] COST-EFFECTIVENESS OF NEW TRIPLET COMBINATIONS WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Pyadushkina, E.
    Derkach, E., V
    [J]. VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [7] COST-EFFECTIVENESS OF DARATUMUMAB ADDED TO LENALIDOMIDE AND DEXAMETHASONE FOR TRANSPLANT INELIGIBLE MULTIPLE MYELOMA
    Narsipur, N.
    Bulla, S.
    Yoo, C.
    Tran, K.
    Do, B.
    Gu, D.
    Chou, Z.
    Wilson, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S35 - S35
  • [8] COST-EFFECTIVENESS OF LENALIDOMIDE-PLUS-DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY: A SOUTH KOREAN PERSPECTIVE
    Vandewalle, B.
    Felix, J.
    Almeida, J.
    Valeska, A.
    Yeo, R.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [9] A COMPREHENSIVE COST-EFFECTIVENESS ANALYSIS OF LENALIDOMIDE FOR MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
    Felix, J.
    Almeida, J.
    Vandewalle, B.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [10] Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial
    Maiese, Eric M.
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    Abraham, Ivo
    Senbetta, Mekre
    [J]. BLOOD, 2017, 130
12345